文献速递技术与安全US

治疗性超声在体内诱导胰岛素释放

Therapeutic Ultrasound-Induced Insulin Release in Vivo.
PubMed 文献 · Ultrasound Med Biol · 2019-12-11

在小鼠临床前模型中,单次5分钟连续超声(1 MHz、1.0 W/cm²)后血清胰岛素中度升高约50 pM,而假手术组下降约60 pM(n<6,p<0.005);葡萄糖和胰高血糖素变化组间无差异,胰腺组织学未见损伤。

要点

  • 治疗性超声可诱导小鼠体内胰岛素释放,幅度约50 pM。
  • 超声后胰岛素变化与假手术组方向相反(升高 vs 下降)。
  • 葡萄糖和胰高血糖素变化组间无差异,胰腺组织学未见损伤。

核心结论

  • 低频低强度治疗性超声在小鼠体内可引起中度但显著的胰岛素升高,且未见胰腺组织学损伤,是评估其作为早期2型糖尿病治疗转化潜力的第一步。

研究设计与样本

  • 临床前小鼠体内模型;治疗组接受单次5分钟连续超声(1 MHz、1.0 W/cm²);采用酶联免疫吸附测定检测血清胰岛素和胰高血糖素;切除胰腺进行组织学分析。

关键影像表现/征象

  • 终末研究中,超声后即刻血胰岛素浓度较基线中度升高约50 pM,而假手术组下降约60 pM(n<6,p<0.005)。
  • 苏木精-伊红染色的终末和存活期胰腺组织比较未见可见差异或损伤证据。

局限性

  • 原文结论称本研究是评估治疗性超声作为早期2型糖尿病治疗转化潜力的第一步。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The tolerability and efficacy of low-frequency, low-intensity therapeutic ultrasound-induced insulin release was investigated in a pre-clinical in vivo murine model. The treatment groups received a single 5-min continuous sonication at 1 MHz and 1.0 W/cm2. Insulin and glucagon levels in the serum were determined using enzyme-linked immunosorbent assay. The pancreas was excised and sectioned for histologic analysis. In terminal studies, we observed a moderate (∼50 pM) but significant increase in blood insulin concentration in vivo immediately after sonication compared with a decrease of approximately 60 pM in sham animals (n < 6, p < 0.005). No difference was observed in the change in glucose or glucagon concentrations between groups. Comparisons of hematoxylin and eosin-stained terminal and survival pancreatic tissue revealed no visible differences or evidence of damage. This study is the first step in assessing the translational potential of therapeutic ultrasound as a treatment for early stages of type 2 diabetes.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Singh T, Suarez Castellanos I, Bhowmick DC, et al. Therapeutic Ultrasound-Induced Insulin Release in Vivo. Ultrasound Med Biol. 2019. PMID: 31837888. doi:10.1016/j.ultrasmedbio.2019.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。